# Effect of Exendin-(9-39) on Glycemic Control in Subjects With Congenital Hyperinsulinism

> **NCT00571324** · PHASE1,PHASE2 · COMPLETED · sponsor: **Diva De Leon** · enrollment: 9 (actual)

## Conditions studied

- Congenital Hyperinsulinism

## Interventions

- **DRUG:** Exendin-(9-39)
- **OTHER:** Vehicle

## Key facts

- **NCT ID:** NCT00571324
- **Lead sponsor:** Diva De Leon
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2017-12-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00571324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00571324, "Effect of Exendin-(9-39) on Glycemic Control in Subjects With Congenital Hyperinsulinism". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00571324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*